MorphoSys AG (MOR): Price and Financial Metrics

MorphoSys AG (MOR)

Today's Latest Price: $25.13 USD

0.09 (-0.36%)

Updated Oct 30 4:00pm

Add MOR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 240 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

MOR Stock Summary

  • With a year-over-year growth in debt of 1,367.78%, MorphoSys AG's debt growth rate surpasses 98.44% of about US stocks.
  • Over the past twelve months, MOR has reported earnings growth of -362.25%, putting it ahead of just 5.3% of US stocks in our set.
  • Revenue growth over the past 12 months for MorphoSys AG comes in at 157.83%, a number that bests 96.28% of the US stocks we're tracking.
  • If you're looking for stocks that are quantitatively similar to MorphoSys AG, a group of peers worth examining would be SRNE, TMDX, VERU, ASX, and NWBO.
  • Visit MOR's SEC page to see the company's official filings. To visit the company's web site, go to

MOR Stock Price Chart Interactive Chart >

Price chart for MOR

MOR Price/Volume Stats

Current price $25.13 52-week high $37.96
Prev. close $25.22 52-week low $18.21
Day low $25.02 Volume 72,000
Day high $25.45 Avg. volume 109,019
50-day MA $29.80 Dividend yield N/A
200-day MA $29.77 Market Cap 3.31B

MorphoSys AG (MOR) Company Bio

MorphoSys AG engages in the research, development, and optimization of therapeutic antibody drug candidates in partnership with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 drugs for the treatment of cancer, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. The company was founded in 1992 and is based in Planegg, Germany.

MOR Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$25.13$0.07 -100%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for MorphoSys AG. To summarize, we found that MorphoSys AG ranked in the 0th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 100%. As for the metrics that stood out in our discounted cash flow analysis of MorphoSys AG, consider:

  • The company's balance sheet shows it gets 58% of its capital from equity, and 42% of its capital from debt. Its equity weight surpasses that of just 20.5% of free cash flow generating stocks in the Healthcare sector.
  • The company's compound free cash flow growth rate over the past 0.25 years comes in at -0.71%; that's greater than just 0.98% of US stocks we're applying DCF forecasting to.
  • MorphoSys AG's weighted average cost of capital (WACC) is 7%; for context, that number is higher than merely 13.55% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

Want more companies with a valuation profile/forecast similar to that of MorphoSys AG? See AGHC, AHPI, ALC, AMRN, and DRAD.

MOR Latest News Stream

Event/Time News Detail
Loading, please wait...

MOR Latest Social Stream

Loading social stream, please wait...

View Full MOR Social Stream

Latest MOR News From Around the Web

Below are the latest news stories about MorphoSys AG that investors may wish to consider to help them evaluate MOR as an investment opportunity.

MorphoSys's CFO to step down

MorphoSys (MOR) has announced that its CFO Jens Holstein, will step down, effective December 31. The company has commenced a search process for the new CFO....

Seeking Alpha | September 30, 2020

MorphoSys AG (MOR) CEO Jean-Paul Kress on Q2 2020 Results - Earnings Call Transcript

MorphoSys AG (MOR) Q2 2020 Earnings Conference Call August 06, 2020, 08:00 AM ET Company Participants Anja Pomrehn - Head of IR Jean-Paul Kress - CEO Jens Holstein - CFO Malte Peters - Chief Research and Development Officer Roland Wandeler - COO Conference Call Participants Jason Butler - JMP Securities...

SA Transcripts on Seeking Alpha | August 9, 2020

Invitation to MorphoSys' Second Quarter and First Half 2020 Results Conference Call on August 6, 2020

MorphoSys' Management team will host a conference call and webcast on August 6, 2020 at 2:00pm CEST (1:00pm BST; 8:00am EDT) to present the second quarter and first half financial results 2020 and the further outlook for 2020.

Yahoo | July 30, 2020

MORNING BID-Fog, stall ... rally

The views expressed are her own.) As U.S. coronavirus cases hit records and reopenings are dialled back, Federal Reserve officials admitted economic growth forecasts from the June policy meeting did not factor in the risk of a second wave. Fed Governor Lael Brainard summed it up as "a thick fog of uncertainty" and said "downside risks predominate." A similar message from the corporate world -- Delta Airlines CEO Ed Bastian said the industry was "at a stall right now."

Yahoo | July 15, 2020

MororphoSys's Licensee Janssen Announces Approval of Tremfya (Guselkumab) by U.S. FDA for Treatment of Adults with Active Psoriatic Arthritis

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / July 14, 2020 / MorphoSys AG (FSE:MOR); Prime Standard Segment; MDAX & TecDAX; (NASDAQ:MOR) announced today that its licensee Janssen Research & Development, ...

Yahoo | July 14, 2020

Read More 'MOR' Stories Here

MOR Price Returns

1-mo -16.73%
3-mo -21.86%
6-mo -1.95%
1-year -9.80%
3-year N/A
5-year N/A
YTD -29.55%
2019 40.99%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Continue Researching MOR

Here are a few links from around the web to help you further your research on MorphoSys AG's stock as an investment opportunity:

MorphoSys AG (MOR) Stock Price | Nasdaq
MorphoSys AG (MOR) Stock Quote, History and News - Yahoo Finance
MorphoSys AG (MOR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.9026 seconds.